25 mayo 2016

STIFEL AND KBW COMBINE FOR NO. 1 RANKING IN 2016 THOMSON REUTERS STARMINE ANALYST AWARDS .

P.J.: Stifel y sus Analistas reconicidos como " Los Mejores " . Como Todos Sabeís esta casa de Analistas es una de las que analiza y publica Informes sobre PharmaMar . En el último informe subió el Precio Objetivo de PharmaMar de los 4,67 euros hasta los 5, 90 euros ...  Un Informe Firmado por Max Herrmann que ha sido precisamente uno de los Más Premiados y Reconocido .

************************************************************
ST. LOUIS, May 24, 2016 — 

Stifel Financial Corp. (NYSE: SF) today announced that its Stifel, Nicolaus & Company, Incorporated (“Stifel”) and Keefe, Bruyette & Woods (“KBW”) subsidiaries combined to win 18 awards in the 2016 Thomson Reuters StarMine Analyst Awards, ranking the firm tied for first in number of awards won among 167 qualifying U.S. firms. With more than 1,400 companies coverage in the U.S., Stifel also ranks as the overall largest provider of equity research and as the largest provider of small- and mid-cap coverage.

“We are proud of our analysts’ accomplishments and their recognition by StarMine, across all our brands and geographies,” said Hugh Warns, Global Head of Research. “While we are thrilled with earning our first overall No. 1 ranking, we are even happier to report that it continues a 10-year track record of top 10 rankings in the survey (including firms acquired by Stifel). This consistency is what impresses me most about our team and shows that our analysts are committed to using their industry experience and expertise to add value and drive excess returns for our clients.”

Performance by Subsidiary:

Stifel

In the U.S., Stifel analysts won 15 awards, including five No. 1 industry rankings. Stifel’s Benjamin Nolan earned a No. 10 overall ranking in the earnings estimate accuracy category out of 1,870 analysts.

“We are honored to receive a No. 1 ranking,” said Keith Gay, Director of U.S. Research for Stifel. “This award is a result of our analysts’ hard work and deep industry expertise. It also reflects our strong commitment to rigorous, high-quality fundamental equity research,”


KBW

KBW analysts added three awards to the firm’s total. Notable among KBW’s results was Bose George extending his winning streak to four years. “KBW’s performance speaks to our consistency in providing our clients with high-quality, in-depth analysis,” said Fred Cannon, Global Director of Research for KBW. “These awards reflect our dedication to our clients.”


Stifel Nicolaus Europe Limited

Analysts from Stifel’s European subsidiary won four awards in the Thomson Reuters StarMine United Kingdom & Ireland Analyst Awards, including three No. 1 industry rankings and Robin Haworth’s No. 8 overall ranking in stock picking. Stifel Europe also won one award in the Thomson Reuters StarMine Europe Analyst Awards. “We are proud to be recognized for our industry expertise and our focus on high-quality fundamental research,” said Hector Forysthe, Head of European Research.


For a complete listing of the firm’s awards, please see below.


About the Thomson Reuters StarMine Analyst Awards

The StarMine Analyst Awards recognize sell-side securities analysts based on the returns of their buy/sell recommendations and the accuracy of their earnings estimates. In determining the winners, StarMine identified the top three earnings estimators and stock pickers in 64 industries, as well as the top ten earnings estimators and stock pickers overall.


About Stifel Research

Stifel’s equity research department is an industry leader in terms of breadth and quality. Stifel covers 1,131 U.S. and European companies across 12 industry groups and 63 sub-sectors. With 963 U.S. stocks under coverage, Stifel is one of the 10 largest providers of U.S. equity research. Stifel is also the No. 2 provider of U.S. small cap equity coverage and a top ten provider of U.S. equity coverage in the consumer & retail, diversified industrials, health care, Internet & media, real estate, technology, and transportation sectors, according to StarMine.


About KBW Research

KBW’s equity research department is an industry leader in specialized financial services. KBW covers 594 U.S. and European companies across 19 sub-sectors and is the largest provider of U.S. equity research in financial institutions. KBW also is the sixth largest provider of U.S. small cap equity coverage and ranks among the top providers in coverage of banks, capital markets, insurance, and thrifts & mortgage finance, according to StarMine.


Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Century Securities Associates, Inc., and in the United Kingdom and Europe through Stifel Nicolaus Europe Limited. The Company’s broker-dealer affiliates provide wealth management, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank & Trust offers a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company’s web site at www.stifel.com.


* * *
Research Media Relations:

Linda Olszewski, (443) 224-1367
THOMSON REUTERS
ANALYST AWARDS
2016 WINNER


U.S.
Earnings Estimate Accuracy
• Benjamin Nolan, No. 10 overall out of 1,874 analysts.
• Stanley Elliott, No. 1 in Construction Materials
• Christopher Growe, No 1. In Food Products (Six-time award winner)
• Christopher Growe, No. 1 in Tobacco
• Benjamin Nolan, No. 1 in Marine
• Paul Westra, No. 1 in Restaurants
• Shlomo Rosenbaum, No. 2 in Professional Services (Two-time award winner)
• Simon Yarmak, No. 2 in Real Estate Investment Trusts
• Simon Yarmak, No. 3 in Hotels & Leisure (Four-time award winner)
• Drew Crum, No. 3 in Leisure Products (Two-time award winner)
Stock Picking
• John Baugh, No. 2 in Household Durables (Four-time award winner)
• Joseph DeNardi, No. 2 in Aerospace & Defense
• Mark Swartzberg, No. 2 in Beverages (Six-time award winner)
• Joseph DeNardi, No. 3 in Airlines
• Annabel Samimy, No. 3 in Pharmaceuticals
Stifel Financial Corp. Winners


U.S.
Earnings Estimate Accuracy
• Bose George, No. 1 in Thrifts & Mortgage Finance (Five-time award winner)
• Joel Jeffrey, No. 2 in Capital Markets (Three-time award winner)
• Jade Rahmani, No. 3 in Household Durables
Stifel, Nicolaus & Company, Incorporated | Member SIPC & NYSE | www.stifel.com
Keefe, Bruyette & Woods | Member SIPC, FINRA & NYSE | www.kbw.com | A subsidiary of Stifel Financial Corp.
Stifel Nicolaus Europe Limited | Authorised and Regulated by the Financial Conduct Authority | A subsidiary of Stifel Financial Corp.


United Kingdom & Ireland


Earnings Estimate Accuracy
• Max Herrmann, No. 1 in Health Care
Stock Picking
• Robin Haworth, No. 8 overall
• Robin Haworth, No. 1 in Energy
• Max Herrmann, No. 1 in Health Care


Europe
Stock Picking
• Max Herrmann, No. 2 in Pharmaceuticals


Yondelis . Janssen Oncology ( J&J ) Announces New Advances in Their Compound Yondelis ( Trabectedin ) at ASCO 2016 .

Abstract 11060 :

Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.

Monday, June 6th /// 8:00 – 11:30 a.m. CDT .

***************************************

Abstrac 11061 :

Patient-reported outcomes from randomized, phase 3 study of trabectedin (T) vs.dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS) .

Monday, June 6th /// 8:00 – 11:30 a.m. CDT .

***************************************

Abstrac 11064 :

Trabectedin (T)-related liver toxicity: Results of a pharmacokinetic study with T in patients with

hepatic dysfunction (OVC1004) and experience from a Phase 3 clinical trial (SAR3007).

Monday, June 6th /// 8:00 – 11:30 a.m. CDT .

****************************************


About YONDELIS® (trabectedin) :

YONDELIS® (trabectedin) is a synthetically produced anti-tumor agent, originally derived from the sea squirt Ecteinascidia turbinata. It works by binding to the DNA of cancer cells and disrupting their normal cell activity, which causes cell death. More information, including the full prescribing information, is available at www.YONDELIS.com.

YONDELIS is approved in nearly 80 countries in North America, Europe, South America and Asia. In October 2015, YONDELIS was FDA approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline containing regimen.

Under a licensing agreement with PharmaMar, Janssen Products, LP has the rights to develop and sell YONDELIS globally except in Europe, where PharmaMar SA holds the rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceutical Co., Ltd.

...

Pfizer confirma el crecimiento y la diversidad de su investigación en oncología en ASCO 2016 .

En relación : Pfizer compra la farmacéutica Anacor Pharamaceuticals por 5.200 millones de dólares .


 crecimiento y la diversidad de su investigación en oncología24-05-2016 // Escrito por redacción prnoticias .

En la próxima edición de ASCO, Pfizer tendrá su mayor presencia en los últimos 52 años de historia de este congreso americano que se celebra en Chicago entre el 3 y el 7 de junio. En estos días, Pfizer presentará más de 40 abstracts que muestran el crecimiento y diversidad de su investigación en Oncología, tanto en tipos de tumores como en mecanismos de acción. Tendrán lugar 8 presentaciones orales y 5 discusiones de pósters que representan los resultados de los avances internos y de colaboraciones externas de la compañía.

Entre los principales resultados, se presentarán, por primera vez, datos de un estudio de combinación con una inmunoterapia pionera que combina un agonista 4-1BB y un inhibidor checkpoint como nueva estrategia. Asimismo se publicarán datos de dos fármacos innovadores palbociclib y Xalkori® (crizotinib), los avances en la investigación de avelumab, anticuerpo monoclonal anti-PD-L1 tipo IgG1, que está en desarrollo en colaboración con Merck, y una nueva generación de inhibidores de la tirosina quinasa frente ALK y ROS 1, el lorlatinib.

Al respecto, José Alonso, director de la unidad de Oncología en España, señala que “nuestra presencia significativa en ASCO subraya nuestro compromiso a largo plazo con la Oncología y la fortaleza de nuestras colaboraciones para proporcionar nuevos fármacos dirigidos a diferentes tipos de tumores”. Y añade “estamos deseando compartir nuestros descubrimientos con la comunidad científica con la esperanza de que nuestros esfuerzos colectivos contribuyan al avance de nuevos enfoques que redefinan la vida del paciente con cáncer”.

...

Myeloma Patients Europa ha denunciado ante los tribunales a la española Begoña Barragán por desviar presuntamente más de 83.000 euros de esta organización para pacientes con cáncer mientras fue su tesorera entre 2013 y 2014.

Comunicado Oficial : http://www.mpeurope.org/news/statement-from-mpe-on-the-court-case-it-has-taken-against-its-former-treasurer-ms-begona-barragan/


MARÍA VALERIO // Madrid /// 25/05/2016 .

La asociación europea de pacientes con mieloma ha denunciado ante los tribunales a la española Begoña Barragán por desviar presuntamente más de 83.000 euros de esta organización para pacientes con cáncer mientras fue su tesorera entre 2013 y 2014.

Myeloma Patients Europa ha anunciado esta demanda en su página web, en la que explica que Barragán habría ocultado y destruido además información financiera del grupo europeo mientras ejerció como tesorera, lo que habría impedido a esta asociación descubrirlo antes.Según esta organización sin ánimo de lucro -que aglutina a 36 asociaciones europeas de pacientes con mieloma-, dedicada a los pacientes con este tipo de cáncer, su ex tesorera española habría desviado fraudulentamente los 83.750 euros a dos asociaciones españolas de las que es responsable: AEAL (asociación española de afectados por linfoma) y Fundaseth. El comunicado señala que lo habría hecho a través de cuatro transferencias no autorizadas desde la cuenta bancaria de MPE a las de AEAL y Fundaseth, "que estaban bajo su control y responsabilidad".

...

Más del 30 % de los mayores de 75 años desarrollará Alzheimer .

Los expertos recuerdan que solo un 4 % de los casos de Alzheimer tiene un origen hereditario, debido a mutaciones de genes .

EUROPA PRESS 24 de mayo de 2016.

«En España en la actualidad hay 800.000 personas diagnosticadas de Alzheimer. En el caso de las personas mayores de 75 años, más del 30 % desarrollará esta enfermedad». Así lo asegura el vicedecano de la Facultad de Farmacia de la Universidad de Navarra e investigador del Programa de Neurociencias del Centro de Investigación Médica Aplicada (CIMA), Alberto Pérez-Mediavilla, quien participará este miércoles en el ciclo de conferencias de ciencia Pint of Science.

Según recuerda el experto, ahora mismo la investigación sobre la enfermedad de Alzheimer (EA) se centra en terapias dirigidas a neutralizar las moléculas tau y amiloide que se producen dentro de las neuronas y que resultan tóxicas: «Hoy sabemos que estas sustancias causan la enfermedad, pero desconocemos por qué se generan en más cantidad en los cerebros de los enfermos de Alzheimer y por qué no las eliminan, como sucede en los cerebros de las personas sanas».

...